News For BMY From The Last 14 Days Check below for free stories on BMY the last two weeks.
There are 7 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 13, 2012
|
| 17:05 EDT |  | BMY |
| | 07:31 EDT | | BMY |
| theflyonthewall.com: | Bristol-Myers announces completion of tender offer for Inhibitex shares | | The tender offer expired at midnight, New York City time, on February 10, 2012. As of the expiration of the offer, 77,532,611 shares of common stock of Inhibitex were validly tendered and not withdrawn in the tender offer. All of such shares have been accepted for payment in accordance with the terms of the tender offer. As a result of the tender offer, Bristol-Myers now owns, together with its affiliates, approximately 91% of the outstanding shares of Inhibitex, which will allow Bristol-Myers to complete and close the merger and acquisition of Inhibitex today without stockholder approval. :theflyonthewall.com |
|
|
February 10, 2012
|
| 11:58 EDT |  | BMY |
|
|
February 9, 2012
|
| 16:27 EDT | | BMY |
| theflyonthewall.com: | Leerink's biotech and pharmaceuticals analysts hold a conference call | | Biotech Analysts Schimmer and Liang, along with Pharmaceuticals Analyst Fernandez, review the reimbursement process for drugs in France on an Analyst/Industry conference call. Relevant covered companies ACOR, AMGN, AMLN, AUXL, BIIB, BMY, GILD, HGSI, ITMN, JNJ, NVS, PFE and VRTX may be included on the Analyst/Industry conference call to be held on February 10 at 11 am. :theflyonthewall.com |
|
|
February 8, 2012
|
| 23:32 EDT | | BMY |
| | 05:32 EDT | | BMY |
| theflyonthewall.com: | Sanofi, Bristol-Myers collect damages in Plavix patent litigation with Apotex | | Sanofi (SNY) and Bristol-Myers Squibb (BMY) announced that Apotex has made payment in the amount of $442,209,362 to Sanofi and Bristol-Myers Squibb to satisfy the damages ruling of the Plavix, or clopidogrel bisulfate, patent infringement case against Apotex. This payment, which follows the decision of the U.S. Court of Appeals for the Federal Circuit in October 2011 upholding the payment of damages to the companies by Apotex, represents the final phase of the Plavix patent litigation between the companies and Apotex, which was initiated on March 21, 2002. Sanofi and Bristol-Myers Squibb were also awarded $1,258,682 in post-judgment interest and $900,000 in costs in addition to the damages award. :theflyonthewall.com |
|
|
February 3, 2012
|
| 07:31 EDT | | BMY |
| theflyonthewall.com: | Bristol-Myers announces expiration of waiting period for Inhibitex acquisition |
 Subscribe for More Information :theflyonthewall.com |
|
|
|
